Mega Lifesciences Valuation
Is MEGA-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MEGA-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEGA-R (THB40) is trading below our estimate of fair value (THB58.49)
Significantly Below Fair Value: MEGA-R is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEGA-R?
Other financial metrics that can be useful for relative valuation.
What is MEGA-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿34.87b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | 9.9x |
PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does MEGA-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 19.5x | ||
BLC Bangkok Lab And Cosmetic | 20x | n/a | ฿3.1b |
LAB B Genomma Lab Internacional. de | 16.8x | 28.6% | Mex$17.6b |
688513 Chengdu Easton Biopharmaceuticals | 27.7x | 21.8% | CN¥6.7b |
603367 Cisen Pharmaceutical | 13.4x | n/a | CN¥7.1b |
MEGA-R Mega Lifesciences | 17.3x | 10.9% | ฿34.9b |
Price-To-Earnings vs Peers: MEGA-R is good value based on its Price-To-Earnings Ratio (17.3x) compared to the peer average (19.5x).
Price to Earnings Ratio vs Industry
How does MEGA-R's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: MEGA-R is good value based on its Price-To-Earnings Ratio (17.3x) compared to the Asian Pharmaceuticals industry average (24.7x).
Price to Earnings Ratio vs Fair Ratio
What is MEGA-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 17.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEGA-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.